The human civilization is reeling under COVID19 pandemic with no promising news of any effective treatment
against the infection till date. A number of drugs have been repurposed without any remarkable efficacy. Amidst the
crisis, utilising immunomodulators for boosting host immunity to mitigate disease severity and infectivity appears a viable
option. In this article, we have explored the contemporary scientific evidence about levamisole for its potential use in
COVID 19. Though the primary pharmacological use of the drug is as an anthelminthic, its immunostimulatory action has
been shown to increase T-cell function, neutrophilic chemotaxis and immunoglobulin production both in vitro and in vivo.
Clinically, the drug has been used with limited success in treatment of herpes and HIV. The potential role of the drug in
COVID 19 stems from the fact that the immunostimulant action can initiate a strong immune response and surmount the
surreptitious virus which evades host cell immunity. However, great caution has to be exercised in deciding the dose
schedule because the drug-disease interaction, especially the fatal hyperimmune response, are unknown and unpredictable.
Being a widely available drug, enlisted in WHO List of Essential Medicine, without any major safety issue, the drug is
already in clinical trials the world over. As the pandemic continues to ravage mankind with unabated intensity, any
favourable outcome is eagerly awaited from the ongoing trials with levamisole and other drugs.